C520 Stock Overview
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for C520 from our risk checks.
Enovis Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.00 |
| 52 Week High | US$59.00 |
| 52 Week Low | US$41.20 |
| Beta | 2.07 |
| 1 Month Change | -2.80% |
| 3 Month Change | -1.89% |
| 1 Year Change | 0% |
| 3 Year Change | -52.64% |
| 5 Year Change | -34.84% |
| Change since IPO | 29.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| C520 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.5% | -5.1% | -1.5% |
| 1Y | 0% | -9.0% | 0.9% |
Return vs Industry: C520 exceeded the German Medical Equipment industry which returned -6.2% over the past year.
Return vs Market: C520 matched the German Market which returned -0.4% over the past year.
Price Volatility
| C520 volatility | |
|---|---|
| C520 Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C520 has not had significant price volatility in the past 3 months.
Volatility Over Time: C520's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Matt Trerotola | www.enovis.com |
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Enovis Corporation Fundamentals Summary
| C520 fundamental statistics | |
|---|---|
| Market cap | €2.90b |
| Earnings (TTM) | -€51.08m |
| Revenue (TTM) | €1.60b |
1.8x
P/S Ratio-55.7x
P/E RatioIs C520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C520 income statement (TTM) | |
|---|---|
| Revenue | US$1.71b |
| Cost of Revenue | US$713.67m |
| Gross Profit | US$993.53m |
| Other Expenses | US$1.05b |
| Earnings | -US$54.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 58.20% |
| Net Profit Margin | -3.18% |
| Debt/Equity Ratio | 13.6% |
How did C520 perform over the long term?
See historical performance and comparison